To be Available in March 2016
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it received a
510(k) clearance (K152954) from the U.S. Food and Drug Administration
(FDA) for an upgraded version of Quell, the company's over-the-counter,
100% drug free chronic pain relief wearable. Under this 510(k), the
Quell device can be controlled directly via the Quell Relief smartphone
app. This provides an unprecedented level of convenience and comfort
when using Quell to treat chronic pain.
"This 510(k) further advances Quell technology by allowing the device to
be conveniently and safely controlled via a smartphone," said Shai
Gozani, M.D., Ph.D., President and CEO NeuroMetrix. "It is a clear
example of our unwavering commitment to creating the most clinically
effective and technologically innovative wearable therapeutic solution
for people suffering from chronic pain. It is only fitting that we are
making this announcement at CES 2016 which is the international showcase
for consumer technology breakthroughs."
Quell is designed for people with a wide range of chronic pain
conditions. The latest version of Quell gives users the option to
control their therapy via a mobile app and includes several additional
enhancements including extended battery life and advanced sleep
tracking. It will be available in March 2016. NeuroMetrix will have a
free upgrade program for existing Quell users who send in their previous
generation devices when the new version is available in March.
NeuroMetrix is exhibiting Quell at the CES in Las Vegas from January 6 -
9, at Sands Booth #73313. Quell is a finalist for the Last Gadget
Standing award, which includes some of the most breakthrough products at
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006232/en/
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Laura Wagstaff, 646-371-7595
Source: NeuroMetrix, Inc.
News Provided by Acquire Media